Intervention not reported
Resolution of ear discharge ‐ measured after 4 weeks · CSOM, recurrence of CSOM or suppuration following mastoidectomy or tympanoplasty
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Interventions · people with liver cirrhosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Rifaximin (1 RCT, 299 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes rifaximin (1 RCT, 299 participants) (very low certainty).
1 finding from 1 review
OR 1.01 [0, 853.21]
Studies not reported
Very low
Intervention not reported
Norfloxacin (no direct RCT) · people with liver cirrhosis
It is very uncertain whether the intervention changes norfloxacin (no direct RCT) (very low certainty).
1 finding from 1 review
OR 11.85
Studies not reported
Very low
Intervention not reported
Rifaximin (3 RCTs, 418 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes rifaximin (3 RCTs, 418 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Ciprofloxacin (3 RCT; 255 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes ciprofloxacin (3 RCT; 255 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Sulfamethoxazole + trimethoprim (1 RCT, 60 participants) · people with liver cirrhosis
The intervention may leads to lower sulfamethoxazole + trimethoprim (1 RCT, 60 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Norfloxacin (1 RCT, 68 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes norfloxacin (1 RCT, 68 participants) (very low certainty).
1 finding from 1 review
HR 0.93 [0.31, 3.44]
Studies not reported
Very low
Intervention not reported
Ciprofloxacin (no direct RCT) · people with liver cirrhosis
It is very uncertain whether the intervention changes ciprofloxacin (no direct RCT) (very low certainty).
1 finding from 1 review
HR 0.62 [0.12, 3.31]
Studies not reported
Very low
Intervention not reported
Sulfamethoxazole + trimethoprim (no direct RCT) · people with liver cirrhosis
It is very uncertain whether the intervention changes sulfamethoxazole + trimethoprim (no direct RCT) (very low certainty).
1 finding from 1 review
HR 2.62 [0.62, 11.91]
Studies not reported
Very low
Intervention not reported
Rifaximin (2 RCTs, 106 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes rifaximin (2 RCTs, 106 participants) (very low certainty).
1 finding from 1 review
HR 7.8 [0.13, 4647.11]
Studies not reported
Very low
Intervention not reported
Norfloxacin (3 RCTs, 255 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes norfloxacin (3 RCTs, 255 participants) (very low certainty).
1 finding from 1 review
HR 0.16 [0, 1.56]
Studies not reported
Very low
Intervention not reported
No active intervention · people with liver cirrhosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Norfloxacin + neomycin (1 RCT, 22 participants) · people with liver cirrhosis
The intervention may leads to lower norfloxacin + neomycin (1 RCT, 22 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Norfloxacin + rifaximin (no direct RCT) · people with liver cirrhosis
It is very uncertain whether the intervention changes norfloxacin + rifaximin (no direct RCT) (very low certainty).
1 finding from 1 review
Intervention not reported
Rifaximin (3 RCTs, 575 participants) · people with liver cirrhosis
The intervention may leads to lower rifaximin (3 RCTs, 575 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Norfloxacin (3 RCTs, 439 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes norfloxacin (3 RCTs, 439 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Rifaximin (3 RCTs, 479 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes rifaximin (3 RCTs, 479 participants) (very low certainty).
1 finding from 1 review
HR 0.57 [0.33, 1]
Studies not reported
Very low
Intervention not reported
Norfloxacin (4 RCTs, 546 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes norfloxacin (4 RCTs, 546 participants) (very low certainty).
1 finding from 1 review
HR 0.74 [0.49, 1.09]
Studies not reported
Very low
Intervention not reported
Ciprofloxacin (3 RCTs, 255 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes ciprofloxacin (3 RCTs, 255 participants) (very low certainty).
1 finding from 1 review
HR 0.61 [0.31, 1.16]
Studies not reported
Very low